Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018278 · ClinicalTrials.gov registry record · Phase 4
Electrophysiologic Measures of Treatment Response in Alzheimer Disease
A Phase 4 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00018278 is a Phase 4 study that has completed, run by US Department of Veterans Affairs.
The verdict
NCT00018278, a Phase 4 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
Interventions
- DRUG Aricept
- DRUG Exelon
- DRUG Nicoderm Patch
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-10 |
| Est. Completion | 2001-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00018278
The ClinicalTrials.gov registry entry for NCT00018278 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aricept is the first listed.
NCT00018278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00018278 about?
NCT00018278 is a clinical study titled "Electrophysiologic Measures of Treatment Response in Alzheimer Disease". The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
What is the current status of trial NCT00018278?
This trial is currently completed. It is a Phase 4 study. The study started on 1998-10. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00018278?
The interventions under investigation include: Aricept (DRUG), Exelon (DRUG), Nicoderm Patch (DRUG).
Who is sponsoring clinical trial NCT00018278?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.